Contineum Therapeutics Inc
CTNM5.800USD
-0.160-2.68%
收盘 08/04, 16:00（美东）报价延迟15分钟
150.05M总市值
亏损市盈率 TTM
关于 Contineum Therapeutics Inc 公司
Continum Therapeutics, Inc. 是一家临床阶段的生物制药公司。该公司专注于发现和开发新型口服小分子疗法，这些疗法针对与特定临床损伤相关的生物途径，用于治疗具有高度未满足需求的神经科学、炎症和免疫学 (NI&I) 适应症。其产品线包括 PIPE-791、CTX-343 和 PIPE-307。其主要资产 PIPE-791 是一种新型脑渗透性溶血磷脂酸 1 受体 (LPA1R) 小分子抑制剂，正在开发用于特发性肺纤维化 (IPF) 和进行性多发性硬化症 (Progressive MS)。该公司正在开发 CTX-343，一种外周受限的 LPA1R 拮抗剂，以进一步扩大涉及 LPA1R 拮抗作用的临床适应症。其第二种候选药物 PIPE-307 是一种新型小分子选择性 M1R 抑制剂，目前正在临床开发中，用于治疗抑郁症和复发缓解型 MS (RRMS)。
公司简介
公司代码CTNM
公司名称Contineum Therapeutics Inc
上市日期Apr 05, 2024
CEOMr. Carmine Stengone
员工数量41
证券类型Ordinary Share
年结日Apr 05
公司地址3565 General Atomics Court, Suite 200
城市SAN DIEGO
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编92121
电话18583335280
网址https://www.contineum-tx.com/
公司代码CTNM
上市日期Apr 05, 2024
CEOMr. Carmine Stengone
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Timothy Watkins, M.D.
Dr. Timothy Watkins, M.D.
Chief Medical Officer and Head of Development
Chief Medical Officer and Head of Development
--
--
Dr. Diego Miralles, M.D.
Dr. Diego Miralles, M.D.
Director
Director
--
--
Ms. Sarah Boyce
Ms. Sarah Boyce
Independent Director
Independent Director
--
--
Ms. Lori M. Lyons-Williams
Ms. Lori M. Lyons-Williams
Independent Director
Independent Director
--
--
Mr. Evert B. (Eef) Schimmelpennink
Mr. Evert B. (Eef) Schimmelpennink
Independent Director
Independent Director
--
--
Ms. Kristina Haeckl
Ms. Kristina Haeckl
Senior Vice President - Regulatory Affairs
Senior Vice President - Regulatory Affairs
--
--
Mr. Carmine Stengone
Mr. Carmine Stengone
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Mr. Troy A. Ignelzi
Mr. Troy A. Ignelzi
Independent Director
Independent Director
--
--
Mr. John Healy
Mr. John Healy
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
--
--
Dr. Daniel S. Lorrain, Ph.D.
Dr. Daniel S. Lorrain, Ph.D.
Chief Science Officer
Chief Science Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Timothy Watkins, M.D.
Dr. Timothy Watkins, M.D.
Chief Medical Officer and Head of Development
Chief Medical Officer and Head of Development
--
--
Dr. Diego Miralles, M.D.
Dr. Diego Miralles, M.D.
Director
Director
--
--
Ms. Sarah Boyce
Ms. Sarah Boyce
Independent Director
Independent Director
--
--
Ms. Lori M. Lyons-Williams
Ms. Lori M. Lyons-Williams
Independent Director
Independent Director
--
--
Mr. Evert B. (Eef) Schimmelpennink
Mr. Evert B. (Eef) Schimmelpennink
Independent Director
Independent Director
--
--
Ms. Kristina Haeckl
Ms. Kristina Haeckl
Senior Vice President - Regulatory Affairs
Senior Vice President - Regulatory Affairs
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 7月29日 周二
更新时间: 7月29日 周二
持股股东
股东类型
持股股东
持股股东
占比
RA Capital Management, LP
11.09%
Johnson & Johnson Innovation-JJDC, Inc.
10.34%
Suvretta Capital Management, LLC
8.99%
Franklin Advisers, Inc.
8.23%
Perceptive Advisors LLC
7.53%
Other
53.83%
持股股东
持股股东
占比
RA Capital Management, LP
11.09%
Johnson & Johnson Innovation-JJDC, Inc.
10.34%
Suvretta Capital Management, LLC
8.99%
Franklin Advisers, Inc.
8.23%
Perceptive Advisors LLC
7.53%
Other
53.83%
股东类型
持股股东
占比
Venture Capital
29.30%
Investment Advisor/Hedge Fund
20.96%
Investment Advisor
16.09%
Hedge Fund
15.95%
Private Equity
7.53%
Individual Investor
1.82%
Sovereign Wealth Fund
0.89%
Research Firm
0.25%
Bank and Trust
0.06%
Other
7.16%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
117
15.65M
81.77%
-1.46M
2025Q1
118
15.85M
82.82%
-1.26M
2024Q4
110
17.13M
89.94%
+2.97M
2024Q3
93
14.98M
78.62%
+2.09M
2024Q2
74
14.21M
74.59%
+7.65M
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Johnson & Johnson Innovation-JJDC, Inc.
1.98M
10.34%
--
--
Mar 31, 2025
Suvretta Capital Management, LLC
1.72M
8.99%
--
--
Mar 31, 2025
Franklin Advisers, Inc.
1.58M
8.23%
+130.62K
+9.04%
Mar 31, 2025
Perceptive Advisors LLC
1.44M
7.53%
--
--
Mar 31, 2025
Versant Ventures
918.16K
4.8%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
810.32K
4.23%
+118.44K
+17.12%
Mar 31, 2025
The Vanguard Group, Inc.
803.43K
4.2%
-5.66K
-0.70%
Mar 31, 2025
Sectoral Asset Management Inc.
800.79K
4.18%
--
--
Mar 31, 2025
HHLR Advisors, Ltd.
669.34K
3.5%
--
--
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
iShares Micro-Cap ETF
0.01%
Schwab U.S. Small-Cap ETF
0%
iShares Neuroscience and Healthcare ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
Royce Quant Small-Cap Quality Value ETF
0%
ProShares Hedge Replication ETF
0%
Janus Henderson Small Cap Growth Alpha ETF
0%
Janus Henderson Small/Mid Cap Growth Alpha ETF
0%
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
查看更多
iShares Micro-Cap ETF
占比0.01%
Schwab U.S. Small-Cap ETF
占比0%
iShares Neuroscience and Healthcare ETF
占比0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
占比0%
Royce Quant Small-Cap Quality Value ETF
占比0%
ProShares Hedge Replication ETF
占比0%
Janus Henderson Small Cap Growth Alpha ETF
占比0%
Janus Henderson Small/Mid Cap Growth Alpha ETF
占比0%
Global X Russell 2000 ETF
占比0%
Proshares Ultra Russell 2000
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
